Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists formetastatic disease. Similarly to cutaneousmelanoma, up to 50%of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.
Rossi, E., Maiorano, B. A., Pagliara, M. M., Maria Grazia Sammarco,, Tommaso, D., Martini, M., Rindi, G., Bria, E., Blasi, M. A., Tortora, G., Schinzari, G., Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma, <<FRONTIERS IN ONCOLOGY>>, 2019; 9 (april): 1-5. [doi:10.3389/fonc.2019.00232] [http://hdl.handle.net/10807/134546]
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
Rossi, Ernesto
Primo
;Maiorano, Brigida Anna;Pagliara, Monica Maria;Martini, Maurizio;Rindi, Guido;Bria, Emilio;Blasi, Maria Antonietta;Tortora, Giampaolo;Schinzari, GiovanniUltimo
2019
Abstract
Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists formetastatic disease. Similarly to cutaneousmelanoma, up to 50%of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
